HeartFlow

Mountain View, CA, United States (formerly; relocated to San Francisco, CA in November 2025)  All United States companies → — Founded 2007
Imaging AI Specialist Specialty-Focused AI
Cardiology Radiology
Cardiology AI Radiology & Imaging AI
Public

Products

HeartFlow Analysis
HeartFlow
Cardiology AI
HeartFlow Analysis is a commercial-stage medical technology company providing software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans.

See all 1 product →

About HeartFlow

HeartFlow is a commercial-stage medical technology company that utilizes artificial intelligence (AI) and deep learning to provide a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The company’s core technology transforms standard coronary computed tomography angiography (CCTA) scans into personalized, 3D digital models of a patient’s coronary arteries. This allows physicians to assess the impact of blockages on blood flow (Fractional Flow Reserve derived from CT, or FFRCT Analysis) and to quantify and characterize plaque (Plaque Analysis), offering insights previously only available through invasive procedures.

The HeartFlow platform aims to enhance the care paradigm for patients with CAD by providing precision tools and insights to optimize care delivery and achieve better outcomes. The technology is designed to help clinicians efficiently interpret CCTA scans, detect CAD early, determine the benefit of revascularization, and personalize treatment plans. HeartFlow’s solutions are commercially available in the United States, Canada, Europe, and Japan, and are supported by clinical evidence and guidelines from organizations like the ACC/AHA.

Focus Areas

coronary artery disease (CAD) management AI-driven analysis 3D heart modeling non-invasive diagnostics fractional flow reserve computed tomography (FFRct) plaque analysis roadmap analysis PCI planning

Business Intelligence

TechnologyAI-driven platform, cloud-based infrastructure (FFRCT 2nd Generation), deep learning, high-performance computing, Amazon Web Services (AWS) cloud

What Physicians Need to Know

Coronary Artery Disease (CAD) Diagnosis
HeartFlow transforms standard Coronary Computed Tomography Angiography (CCTA) scans into personalized, color-coded 3D models of the coronary arteries. This allows for a non-invasive and highly accurate diagnosis of CAD, providing insights into both the extent of the disease and its impact on blood flow.
AI-Powered 3D Modeling
Leveraging deep learning and computational fluid dynamics, HeartFlow creates a personalized digital 3D model of a patient's coronary arteries from CCTA images. This model is used to simulate blood flow and assess the impact of blockages.
Fractional Flow Reserve-Computed Tomography (FFRCT) Analysis
HeartFlow's FFRCT Analysis provides values along the coronary arteries, helping physicians assess the impact of a blockage on blood flow. This non-invasive physiological simulation aids in determining the need for invasive treatment or medical management.
Plaque Analysis & Staging
HeartFlow Plaque Analysis offers an AI-driven assessment to quantify total plaque volume, determine plaque composition (including high-risk non-calcified plaque), and inform cardiovascular risk. The Plaque Staging system categorizes plaque burden into mild, moderate, severe, or extensive for personalized preventive care.
Roadmap Analysis
Roadmap Analysis provides an intuitive overview of coronary lesions, helping clinicians quickly assess their location and severity. It aims to boost reading efficiency for CCTA scans.
PCI Planning (PCI Navigator)
HeartFlow PCI Navigator is an integrated, AI-driven tool for pre-planning percutaneous coronary interventions (PCI). It provides interventional cardiologists with a patient-specific 3D model detailing anatomy, plaque composition, and lesion-specific physiology to optimize stent placement.
Cardiovascular Risk Stratification
HeartFlow's analyses, particularly Plaque Analysis and Plaque Staging, enable more precise cardiovascular risk stratification by identifying high-risk patients beyond conventional metrics and guiding personalized preventive treatment.
Non-Invasive Diagnostics
All HeartFlow analyses are non-invasive, utilizing existing CCTA scans to provide detailed diagnostic information that traditionally required invasive procedures. This reduces risks, unnecessary tests, and follow-up evaluations for patients.
Physician Tip

HeartFlow's integrated platform, HeartFlow One, provides a comprehensive suite of AI-powered tools (Roadmap, Plaque, FFRCT, Plaque Staging, PCI Navigator) that transform CCTA scans into actionable insights. This allows for more confident and safer differentiation of patients needing invasive treatment versus medical management, often reducing unnecessary invasive procedures. The detailed 3D models and physiological simulations offer a deeper understanding of CAD, enabling personalized treatment pathways and improved patient outcomes. The technology has been shown to change medical management for over half of patients, leading to better-targeted preventive care and significant reductions in cardiac event risk.

HeartFlow delivers detailed insights directly into PACS and EMR systems, streamlining coronary care workflows. The analysis is provided via a secure online interface. HeartFlow's technology stack leverages deep learning and computational fluid dynamics, with a robust data foundation built from over 160 million annotated CTA images. They have also focused on seamless clinical integration and automated documentation processes, working with tools like Jira and GitHub.

Products by HeartFlow

1 product in the directory

HeartFlow Analysis
HeartFlow
Cardiology AI
HeartFlow Analysis is a commercial-stage medical technology company providing software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans.

What the Web Says

HeartFlow offers a non-invasive diagnostic tool called FFRCT Analysis for coronary artery disease (CAD), which uses CT scans to create 3D models of coronary arteries and assess blood flow. This technology aids physicians in determining the necessity of interventions like stenting or bypass surgery. The company's product has received FDA clearance and Medicare billing codes, indicating its growing acceptance in the healthcare industry. While the technology is praised for its ability to provide both anatomical and functional data, employee reviews present a mixed picture of the company culture and management.

Overall: Mixed

Strengths

  • HeartFlow's FFRCT Analysis is a non-invasive diagnostic tool for coronary artery disease.
  • The technology provides both anatomical and functional data, aiding in treatment decisions.
  • It can help avoid unnecessary invasive procedures.
  • HeartFlow was the first AI cardiac imaging tool to receive FDA clearance and Medicare billing codes.
  • Many employees are proud of the company's mission and the life-saving potential of its products.
  • The company offers good benefits and compensation, according to some employees.

Limitations

  • Some CT scan datasets may be unsuitable for FFRCT analysis due to technical issues.
  • Employee reviews indicate concerns about management, work-life balance, and job security.
  • The work environment can be repetitive and stressful for some roles, particularly for analysts.
  • There are mentions of leadership issues and an ego-driven leadership team.
  • Some employees feel that compensation is low compared to Bay Area standards.
  • There is a reported high turnover rate in some departments.

Based on reviews from: indeed.com, theladders.com, elion.health, sourceforge.net, veevohealth.com, bjcardio.co.uk, heartflow.com, comparably.com, greatplacetowork.com, reddit.com, medaiverdict.com, auntminnie.com, g2.com, capterra.com

Last updated: 2026-10-28

Videos

News, demos, and interviews about HeartFlow.

Loading videos...

Videos load interactively. If none appear, search YouTube for HeartFlow →

View all on YouTube

Press & Coverage

Morningstar
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
HeartFlow announced late-breaking one-year results from an independent randomized clinical trial (FUSION trial) demonstrating that its FFRCT Analysis significantly reduced unnecessary invasive heart procedures by 44%. The study was presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in the Journal of the American College of Cardiology (JACC).
2026-08
Investing.com
Heartflow Inc (HTFL) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% and Plaque Momentum...
HeartFlow reported a narrower-than-expected loss for Q2 2026, with adjusted earnings of negative $0.07 per share, surpassing Wall Street's estimates. The company's revenue increased by 48% year-over-year to $64.1 million, driven by strong demand for its coronary artery disease diagnostics.
2026-10
CardiacWire
Heartflow Takes to The Courts Over AI CCTA Tech
HeartFlow has filed a patent infringement lawsuit against Elucid, accusing them of infringing four patents and misappropriating trade secrets related to their CT-derived fractional flow reserve (FFR) product. This follows a similar lawsuit filed against Cleerly in April.
2026-10
HeartFlow
Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning
HeartFlow announced new clinical evidence and the launch of the NAVIGATE-PCI Registry at the American College of Cardiology (ACC) Annual Scientific Session. The company is presenting data reinforcing its AI-powered Plaque Analysis as a leading tool for identifying high-risk patients and guiding medical management.
2026-03
HeartFlow
Heartflow Files Patent Infringement Lawsuit Against Cleerly
HeartFlow filed a patent infringement lawsuit against Cleerly, Inc. in the U.S. District Court for the Eastern District of Texas. HeartFlow asserts that Cleerly's products infringe six of its patents related to AI technology for coronary artery disease.
2026-04
HeartFlow
Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results
HeartFlow reported strong financial results for Q4 and full year 2025, with total revenue of $49.1 million in Q4, a 40% increase year-over-year. The company also provided 2026 annual revenue guidance of $218 million to $222 million.
2026-03
Med-Tech.World
Heartflow data from 20,000-patient registry reveals game-changing insights for coronary care
Data from HeartFlow's DECIDE Registry, a real-world study involving nearly 20,000 patients, showed that the company's AI-powered Plaque Analysis tool led to changes in treatment plans for over half of the studied patients. This indicates a significant impact on personalized care and earlier intervention for coronary artery disease.
unknown
HeartFlow
Heartflow Closes $98 Million Convertible Notes Financing
HeartFlow closed approximately $98 million in convertible notes financing, with investments from Fidelity Management & Research Company and existing investors. The proceeds will support research and development efforts to advance HeartFlow's CCTA+HeartFlow pathway for diagnosing and managing coronary artery disease.
2025-03

Frequently Asked Questions

HeartFlow is a medical technology company that provides AI-driven, non-invasive solutions for diagnosing and managing Coronary Artery Disease (CAD). It utilizes data from a standard Coronary CT Angiography (CCTA) scan to create a personalized, 3D digital model of the patient's coronary arteries. This model allows physicians to analyze blood flow, identify blockages, characterize plaque, and assess the impact of arterial narrowings on blood flow, offering a more accurate understanding of a patient's heart health without invasive procedures.
HeartFlow's AI-powered 3D modeling transforms CCTA scans into dynamic, personalized 3D heart models, assessing both anatomy and physiology. The Fractional Flow Reserve-Computed Tomography (FFRCT) Analysis then uses advanced computational fluid dynamics and deep learning algorithms to simulate blood flow and calculate FFRCT values along the coronary arteries. This helps clinicians identify clinically significant disease and determine the functional impact of blockages on blood flow, information previously available only through invasive methods.
HeartFlow's Plaque Analysis provides a comprehensive, AI-driven assessment of CAD by quantifying total plaque volume and determining plaque composition, including high-risk non-calcified plaque. This information, along with Plaque Staging, helps physicians personalize preventive care and stratify cardiovascular risk. Roadmap Analysis offers visualization and quantification of the location and severity of anatomical narrowings (stenoses) in coronary arteries, assisting in pre-procedural planning for interventions like PCI.
HeartFlow's FFRCT Analysis, Plaque Analysis, and Roadmap Analysis are FDA-cleared. The company adheres to leading international standards including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001, and has a comprehensive compliance program in accordance with HHS-OIG Guidance. HeartFlow provides extensive support, including clinical, operational, technical, and financial resources, such as billing and reimbursement assistance, technology integration, educational materials, and peer-to-peer education.
While HeartFlow does not publicly publish its per-analysis pricing, it provides detailed reimbursement resources to help healthcare providers navigate the landscape for its platform. HeartFlow FFRCT Analysis and Plaque Analysis have dedicated CPT codes and are covered by Medicare and major commercial insurers. Recent CMS decisions have increased reimbursement rates for CCTA, FFRCT, and AI-QPA services, including HeartFlow Plaque Analysis.
HeartFlow is a commercial-stage medical technology company, publicly traded on Nasdaq (HTFL), and was founded in 2007. The company has reported significant revenue growth and is expanding its installed base globally, with its technology adopted by over 1,800 institutions. HeartFlow has strategic partnerships with organizations like Siemens Healthineers and MedAxiom to improve access to and integration of its diagnostic and planning tools.

Investors

Who's funded HeartFlow.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.